Authors
Joanna Domènech-Vivó, Hélène Tubeuf, Romy L S Mesman, Aurelie Drouet, Mélanie Girardi, María Concepción Alonso-Cerezo, Diana Baralle, Nadia Boutry-Kryza, David J Bunyan, Helen J Byers, Sandrine M Caputo, Kathleen B M Claes, Miguel De la Hoya, D Gareth Evans, Laure Frésard, Sophie Krieger, Conxi Lázaro, Mélanie Leone, Eva Macháčková, Mireia Menéndez, Alejandro Moles-Fernández, Gemma Montalban, Erin Mundt, Marcy E Richardson, Elke M Van Veen, Jamie Weyandt, Judith Balmaña, Amanda B Spurdle, Orland Diez, Maaike P G Vreeswijk, Alexandra Martins, Sara Gutiérrez-Enríquez
Published in
American journal of human genetics. Aug 25, 2026. Epub Aug 25, 2026.
Abstract
The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) research consortium conducted a comprehensive study to characterize spliceogenic variants in BRCA1 exon 18. The absence of systematic RNA-based assessment for these variants has led to inconsistent interpretation, limiting accurate classification and management of individuals and their families. The splicing profile of 166 variants was assessed using minigene assays; 32 were additionally analyzed in blood-derived RNA from 51 individuals and 18 in mouse embryonic stem cell (mESC)-based assays to evaluate homology-directed repair (HDR) capacity. mRNA assessment by RT-PCR in blood samples and minigene assays showed a significant positive correlation, with splicing analysis in mESCs displaying highly concordant results. The mESC-based HDR assay showed that the in-frame exon 18 skipping (Δ18) transcript encodes a non-functional protein lacking rescue activity. Linear regression analysis using mESC splicing and functional data indicated that ≥59% of full-length (FL) levels and <34% of Δ18 were associated with benign HDR activity. These thresholds differ from those recommended by the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) specifications for applying BP7_strong(RNA): >30% functional transcripts or <70% non-functional transcripts. Incorporation of RNA splicing evidence into variant interpretation increased pathogenic (28.6%-31.7%) and benign (3.7%-24.4%) classifications while reducing likely pathogenic (19.5%-17.7%), uncertain (18.9%-8.5%), and likely benign (29.3%-17.7%) categories. Experimental mRNA profiling impacted the interpretation of 34% of variants and resolved uncertainty in approximately 10% of cases. Exon 18 skipping was less tolerated, indicating that the degree of splice perturbation required to impair BRCA1 function may depend on the nature of the resulting non-functional transcript.
PMID:
42641601
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 30
- Comments 0